StreetInsider.com News Articles

Form 424B3 CollPlant Biotechnologie

Fri, 17 Jul 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260717/26782511.html

Form 424B3 CollPlant Biotechnologie

Fri, 17 Jul 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260717/26782511.html

Form EFFECT CollPlant Biotechnologie

Fri, 17 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260717/26781541.html

Form EFFECT CollPlant Biotechnologie

Fri, 17 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260717/26781541.html

Form F-3 CollPlant Biotechnologie

Thu, 09 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260709/26753515.html

Form F-3 CollPlant Biotechnologie

Thu, 09 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260709/26753515.html

Form 6-K CollPlant Biotechnologie For: Jul 07

Tue, 07 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26741791.html

Form 6-K CollPlant Biotechnologie For: Jul 07

Tue, 07 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26741791.html

Form 6-K CollPlant Biotechnologie For: Jul 01

Wed, 01 Jul 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260701/26717484.html

Form 6-K CollPlant Biotechnologie For: Jul 01

Wed, 01 Jul 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260701/26717484.html

CollPlant announces $2.6M private placement of shares and warrants

Tue, 30 Jun 2026 08:01:35 -0400

CollPlant Biotechnologies (Nasdaq: CLGN) announced it has entered into a definitive agreement for a private placement expected to raise approximately $2.6 million in gross proceeds, before placement agent fees and other expenses.

The Israel-based regenerative medicine company said it will issue 7,647,061 ordinary shares at a combined purchase price of $0.34 per share, along with two series of unregistered warrants. Series A warrants cover up to 7,647,061 ordinary shares and Series B warrants cover up to 15,294,122 ordinary shares, both with an exercise price of $0.34 per share.

Both warrant series become exercisable on the date of shareholder approval. Series A warrants

CollPlant announces $2.6M private placement of shares and warrants

Tue, 30 Jun 2026 08:01:35 -0400

Both warrant series become exercisable on the date of shareholder approval. Series A warrants

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

Tue, 30 Jun 2026 08:00:00 -0400

REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof), unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

Tue, 30 Jun 2026 08:00:00 -0400

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

Tue, 30 Jun 2026 08:00:00 -0400

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

Tue, 30 Jun 2026 08:00:00 -0400

Form 6-K CollPlant Biotechnologie For: May 29

Fri, 29 May 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260529/26570726.html

Form 6-K CollPlant Biotechnologie For: May 29

Fri, 29 May 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260529/26570726.html

CollPlant (CLGN) Tops Q1 EPS by 3c

Fri, 29 May 2026 07:04:21 -0400

CollPlant (NASDAQ: CLGN) reported Q1 EPS of ($0.21), $0.03 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $73 thousand versus the consensus estimate of $460 thousand.

For earnings history and earnings-related data on CollPlant (CLGN) click here.

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

Form 3 CollPlant Biotechnologie For: Mar 18 Filed by: Evans Hugh M

Mon, 27 Apr 2026 15:40:00 -0400

si-local-file:///var/storage/secattach/20260427/26374310.html

Form 3 CollPlant Biotechnologie For: Mar 18 Filed by: Evans Hugh M

Mon, 27 Apr 2026 15:40:00 -0400

si-local-file:///var/storage/secattach/20260427/26374310.html